AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23048053 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored training on a virtual reality simulator
Number of subjects: 27
Study 23048053 — intervention group
Group type: COMPARATOR
Intervention: No simulator training (control)
Number of subjects: 27
Study 19542207 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant human IL-1Ra) for 13 weeks
Number of subjects: 70
Study 19542207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17295575 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum plus teacher consultation (Level A)
Number of subjects: 1484
Study 17295575 — intervention group
Group type: EXPERIMENTAL
Intervention: Level A plus small-group training (Level B)
Number of subjects: 1484
Study 17295575 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 1484
Study 15368794 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency fistulectomy (Group A)
Number of subjects: 20
Study 15368794 — intervention group
Group type: COMPARATOR
Intervention: Conventional fistulotomy (Group B)
Number of subjects: 20
Study 12229073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking procedures used in Project Towards No Drug Abuse (Project TND)
Number of subjects: 0
Study 9640572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% gentamicin sulfate eyedrops
Number of subjects: 40
Study 9640572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8090461 — intervention group
Group type: EXPERIMENTAL
Intervention: Original strict criteria for progression based on duplicate testing
Number of subjects: 0
Study 8090461 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised criteria for progression with raised requirement for deterioration and repeated duplicate testing
Number of subjects: 0
Study 2768706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3806
Study 2768706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3806
Study 2768706 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive test (combined groups)
Number of subjects: 3806
Study 2768706 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive test
Number of subjects: 3806
Study 71995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadenan
Number of subjects: 20
Study 31238912 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily)
Number of subjects: 20
Study 31238912 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily) + tramadol (5 mg/kg/day PO)
Number of subjects: 20
Study 31238912 — intervention group
Group type: COMPARATOR
Intervention: Standard-dosage ketoprofen (2 mg/kg SC, then 1 mg/kg PO daily)
Number of subjects: 20
Study 29027511 — intervention group
Group type: EXPERIMENTAL
Intervention: Fcomp on
Number of subjects: 10
Study 29027511 — intervention group
Group type: COMPARATOR
Intervention: Fcomp off
Number of subjects: 10
Study 26355973 — intervention group
Group type: EXPERIMENTAL
Intervention: ASO (anterior subapical osteotomy of the mandible)
Number of subjects: 32
Study 26355973 — intervention group
Group type: COMPARATOR
Intervention: BPsO (bilateral parasymphyseal osteotomy of the mandible)
Number of subjects: 32
Study 23403860 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondent-driven sampling (RDS)
Number of subjects: 48
Study 23403860 — intervention group
Group type: COMPARATOR
Intervention: Conventional outreach-based HTC
Number of subjects: 48
Study 23403860 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat incentive ($20)
Number of subjects: 48
Study 23403860 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional incentive ($10-35)
Number of subjects: 48
Study 23403860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both incentive groups
Number of subjects: 48
Study 21606427 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (225 mg/m(2)/d) plus pelvic radiation (50.4 Gy in 28 daily fractions)
Number of subjects: 747
Study 21606427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (225 mg/m(2)/d) plus pelvic radiation (50.4 Gy in 28 daily fractions) and oxaliplatin (60 mg/m(2) weekly × 6)
Number of subjects: 747
Study 19138610 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior joint space injections of sodium hyaluronate
Number of subjects: 120
Study 19138610 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior joint space injections of sodium hyaluronate
Number of subjects: 120
Study 17443855 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 280
Study 17443855 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein repair
Number of subjects: 280
Study 17443855 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP repair
Number of subjects: 280
Study 17443855 — intervention group
Group type: COMPARATOR
Intervention: Tension-free repairs
Number of subjects: 280
Study 15582012 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of dried ethanolic extract of guarana (approx 12% caffeine)
Number of subjects: 28
Study 15582012 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of Panax ginseng (G115)
Number of subjects: 28
Study 15582012 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 75 mg guarana and 200 mg Panax ginseng
Number of subjects: 28
Study 15582012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11328420 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravesical instillation of mitomycin C (20 mg) and cytosine arabinoside (200 mg) 28 times over 2 years
Number of subjects: 25
Study 11328420 — intervention group
Group type: COMPARATOR
Intervention: Non-instillation group
Number of subjects: 25
Study 9849314 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/day
Number of subjects: 86
Study 9849314 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone 100 mg/day
Number of subjects: 86
Study 9849314 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 450 to 600 mg/day
Number of subjects: 86
Study 9849314 — intervention group
Group type: COMPARATOR
Intervention: Benzbromarone (mean final dose 76 mg/day)
Number of subjects: 86
Study 7986969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 9
Study 7986969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.d.
Number of subjects: 9
Study 7986969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg q.d.s.
Number of subjects: 9
Study 7986969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 600 mg
Number of subjects: 9
Study 7986969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 1200 mg
Number of subjects: 9
Study 7986969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2722308 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 450 mg 3‐sn‐polyenyl‐phosphatidylcholine (PPC)
Number of subjects: 20
Study 2722308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30272856 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal with exercise
Number of subjects: 9
Study 30272856 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% protein meal with exercise
Number of subjects: 9
Study 30272856 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% protein meal with exercise
Number of subjects: 9
Study 30272856 — intervention group
Group type: COMPARATOR
Intervention: Standard meal
Number of subjects: 9
Study 30272856 — intervention group
Group type: COMPARATOR
Intervention: 20% protein meal
Number of subjects: 9
Study 30272856 — intervention group
Group type: COMPARATOR
Intervention: 50% protein meal
Number of subjects: 9
Study 27096358 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing therapeutic CPAP
Number of subjects: 45
Study 27096358 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic CPAP (CPAP withdrawal)
Number of subjects: 45
Study 25332469 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (100 mg/test meal)
Number of subjects: 30
Study 25332469 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (200 mg/test meal)
Number of subjects: 30
Study 25332469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at 42.5 mg/test meal
Number of subjects: 30
Study 25332469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at 85 mg/test meal
Number of subjects: 30
Study 23895132 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferol (150 mg/kg)
Number of subjects: 30
Study 23895132 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferol (30 mg/kg)
Number of subjects: 30
Study 23895132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (12 mg/kg)
Number of subjects: 30
Study 23895132 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 23895132 — intervention group
Group type: EXPERIMENTAL
Intervention: Model group (high cholesterol diet)
Number of subjects: 30
Study 20607216 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubovaginal sling (PVS)
Number of subjects: 63
Study 20607216 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 63
Study 20607216 — intervention group
Group type: COMPARATOR
Intervention: Both PVS and TVT
Number of subjects: 63
Study 18166838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 once every 3 weeks)
Number of subjects: 488
Study 18166838 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 once every 3 weeks)
Number of subjects: 488
Study 18166838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed and Docetaxel (pooled data)
Number of subjects: 488
Study 15642751 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion/occupational health program (HP/OHS)
Number of subjects: 0
Study 15642751 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (HP)
Number of subjects: 0
Study 12456545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at Home (HAH)
Number of subjects: 399
Study 12456545 — intervention group
Group type: COMPARATOR
Intervention: Conventional inpatient care
Number of subjects: 399
Study 12456545 — intervention group
Group type: COMPARATOR
Intervention: NHS costs
Number of subjects: 399
Study 10472581 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 30
Study 8734749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular pacing (VVI)
Number of subjects: 11
Study 1661696 — intervention group
Group type: EXPERIMENTAL
Intervention: Active direct current electrotherapy
Number of subjects: 16
Study 1661696 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 16
Study 6256423 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (therapeutic doses given intravenously and orally over 3 days)
Number of subjects: 10
Study 31926597 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA)
Number of subjects: 90
Study 31926597 — intervention group
Group type: COMPARATOR
Intervention: Low-flow sevoflurane anaesthesia (SEVO)
Number of subjects: 90
Study 31185808 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting
Number of subjects: 49
Study 31185808 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-talk
Number of subjects: 49
Study 31185808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systematic psychological method)
Number of subjects: 49
Study 28455746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear treatment
Number of subjects: 41
Study 28455746 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 41
Study 25712577 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of misoprostol (n = 30)
Number of subjects: 90
Study 25712577 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of dinoprostone (n = 30)
Number of subjects: 90
Study 25712577 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 30)
Number of subjects: 90
Study 23873791 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated nickel-titanium wires
Number of subjects: 61
Study 23873791 — intervention group
Group type: COMPARATOR
Intervention: Regular nickel-titanium wires (non-coated)
Number of subjects: 61
Study 23066842 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 474
Study 23066842 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 474
Study 18987964 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive radiation safety program (group-II)
Number of subjects: 41
Study 18987964 — intervention group
Group type: COMPARATOR
Intervention: No safety program (group-I)
Number of subjects: 41
Study 17414237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (15‐mg patch, 4‐mg gum, and/or 10‐mg inhaler)
Number of subjects: 923
Study 17414237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 923
Study 17414237 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 923
Study 17414237 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of cigarette consumption by at least 50% between baseline and 6 months
Number of subjects: 923
Study 16366083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary cutting guide
Number of subjects: 55
Study 16366083 — intervention group
Group type: COMPARATOR
Intervention: Extramedullary cutting guide
Number of subjects: 55
Study 12410126 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitor of specific tyrosine kinase
Number of subjects: 0
Study 12410126 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 9857531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera containing specific antibodies for Staphylococcus aureus and Escherichia coli obtained from immunized rabbits
Number of subjects: 18
Study 9857531 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bacterial strains incubated with asthmatic patients' sera collected after autovaccines treatment
Number of subjects: 18
Study 9857531 — intervention group
Group type: COMPARATOR
Intervention: Anti-IgE antibodies
Number of subjects: 18
Study 9857531 — intervention group
Group type: COMPARATOR
Intervention: Non-specific sera
Number of subjects: 18
Study 7597434 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (Taxol)
Number of subjects: 0
Study 7597434 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with cisplatin or carboplatin
Number of subjects: 0
Study 7597434 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 2404053 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician feedback intervention group (38 patients)
Number of subjects: 89
Study 2404053 — intervention group
Group type: COMPARATOR
Intervention: Control group (41 patients)
Number of subjects: 89
Study 2404053 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician compliance with recommendations
Number of subjects: 89
Study 43650 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural block followed by intravenous prenalterol administration prior to induction of general anaesthesia
Number of subjects: 16
Study 43650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment prior to general anaesthesia)
Number of subjects: 16
Study 31311386 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab + MTX
Number of subjects: 4568
Study 31311386 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 4568
Study 31311386 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab - MTX
Number of subjects: 4568
Study 29879249 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxymetazoline cream 1.0%
Number of subjects: 885
Study 29879249 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 885
Study 27007800 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg preoperatively, one hour prior to surgery)
Number of subjects: 40
Study 27007800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 40
Study 24491375 — intervention group
Group type: EXPERIMENTAL
Intervention: MESNA applied intraoperatively (46 patients)
Number of subjects: 141
Study 24491375 — intervention group
Group type: COMPARATOR
Intervention: MESNA not applied (95 patients)
Number of subjects: 141
Study 22768902 — intervention group
Group type: EXPERIMENTAL
Intervention: Olibra™ fat emulsion (2.1 g twice daily)
Number of subjects: 82
Study 22768902 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.95 g milk fat, twice daily)
Number of subjects: 82
Study 19417772 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity programme with physician meetings, physical activity prescriptions, group counselling and bicycles
Number of subjects: 120
Study 19417772 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity group support programme with pedometers
Number of subjects: 120
Study 19417772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 17495770 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-L (Synthes Spine) lumbar total disc replacement
Number of subjects: 286
Study 17495770 — intervention group
Group type: COMPARATOR
Intervention: Circumferential spinal fusion
Number of subjects: 286
Study 15638100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 2% eye drops
Number of subjects: 40
Study 15638100 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 10% eye drops
Number of subjects: 40
Study 11355378 — intervention group
Group type: COMPARATOR
Intervention: Younger subjects (aged 20-32 years)
Number of subjects: 23
Study 11355378 — intervention group
Group type: EXPERIMENTAL
Intervention: Older subjects (aged 58-69 years)
Number of subjects: 23
Study 9558034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 49
Study 9558034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 49
Study 9558034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7988250 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) - 400 mg/m2 of cyclophosphamide, 40 mg/m2 of doxorubicin, and 60 mg/m2 of cisplatin, administered in four courses at 3-week intervals starting 30 days post-surgery.
Number of subjects: 269
Study 7988250 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 269
Study 2660374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets with normal particle size
Number of subjects: 8
Study 2660374 — intervention group
Group type: COMPARATOR
Intervention: Tablets with coarse particle size
Number of subjects: 8
Study 4600903 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxuridine 5% in 100% dimethyl sulphoxide (DMSO), applied four-hourly for four days
Number of subjects: 118
Study 4600903 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxuridine 25%, applied two-hourly
Number of subjects: 118
Study 4600903 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 118
Study 31804851 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart Biosimilar SAR341402 (SAR‐Asp)
Number of subjects: 597
Study 31804851 — intervention group
Group type: COMPARATOR
Intervention: Originator Insulin Aspart (NN‐Asp)
Number of subjects: 597
Study 31162653 — intervention group
Group type: EXPERIMENTAL
Intervention: Open minimal suture repair
Number of subjects: 65
Study 31162653 — intervention group
Group type: COMPARATOR
Intervention: Totally extraperitoneal repair
Number of subjects: 65
Study 29330984 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone
Number of subjects: 620
Study 29330984 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene
Number of subjects: 620
Study 26569492 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide Treated Nets (ITN) + Indoor Residual Spraying (IRS)
Number of subjects: 160
Study 26569492 — intervention group
Group type: COMPARATOR
Intervention: Insecticide Treated Nets (ITN)
Number of subjects: 160
Study 23635731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg and conjugated estrogens 0.45 mg
Number of subjects: 1843
Study 23635731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg and conjugated estrogens 0.625 mg
Number of subjects: 1843
Study 23635731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1843
Study 23635731 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.45 mg and medroxyprogesterone acetate 1.5 mg
Number of subjects: 1843
Study 21332430 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol plus ipratropium
Number of subjects: 97
Study 21332430 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol only
Number of subjects: 97
Study 19059639 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 12068
Study 19059639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12068
Study 17067970 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge
Number of subjects: 62
Study 17067970 — intervention group
Group type: COMPARATOR
Intervention: Ordinary stroke unit service
Number of subjects: 62
Study 14599711 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 (0.75 pmol kg(‐1) min(‐1))
Number of subjects: 8
Study 14599711 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 (2.25 pmol kg(‐1) min(‐1))
Number of subjects: 8
Study 14599711 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 16792584 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) for 3 years
Number of subjects: 183
Study 16792584 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 183
Study 10479132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim 3 times a week for 8 weeks
Number of subjects: 20
Study 10479132 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times a week for 8 weeks
Number of subjects: 20
Study 10479132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim
Number of subjects: 20
Study 10479132 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir pharmacokinetics
Number of subjects: 20